AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 1, 2008, Pages 62-71

  Zhang, Ce ^a   Marek, Gerard J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2A receptors; AMPA receptor antagonists; Glutamate; Hallucinogens; LY300164; MK 801

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; EGLUMETAD; GLUTAMIC ACID; KAINIC ACID RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE; PSYCHEDELIC AGENT; SEROTONIN 2A RECEPTOR; TALAMPANEL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; EXCITATORY POSTSYNAPTIC POTENTIAL; FRONTAL CORTEX; HEAD MOVEMENT; LOCOMOTION; MALE; NEUROTRANSMISSION; NONHUMAN; PREDICTION; PREFRONTAL CORTEX; RAT;

AMPHETAMINES; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; FRONTAL LOBE; MALE; NEURONS; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, AMPA; SEROTONIN; TREMOR;

EID: 38349049651     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.07.009     Document Type: Article

References (72)

1. Abi-Saab W.M., D'Souza D.C., Moghaddam B., and Krystal J.H. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31 Suppl 2 (1998) 104-109
2. Aghajanian G.K., and Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36 (1997) 589-599
3. Aghajanian G.K., and Marek G.J. Serotonin-glutamate interactions: a new target for antipsychotic drugs. Neuropsychopharmacology 21 (1999) S122-S133
4. Aghajanian G.K., and Rasmussen K. Intracellular studies in the facial nucleus illustrating a simple new method for obtaining viable motoneurons in adult rat brain slices. Synapse 3 (1989) 331-338
5. Benneyworth MA, Garcia E, Smith R, Sanders-Bush E. (2006). Modulation of hallucinogenic drug action by the mGlu2 subtype of metabotropic glutamate receptors. 2006 Neuroscience Meeting Planner. Atlanta, GA, Society for Neuroscience: Program # 197.19.
6. Benneyworth M.A., Xiang Z., Smith R.L., Garcia E.E., Conn P.J., and Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol Fast Forward (2007) [published May 25, 2007]
7. Benvenga M.J., Chaney S.F., Baez M., Britton T.C., Hornback W.J., Monn J.A., et al. Attenuation of DOI-induced head twitches in mGluR2 KO mice. FASEB J 20 (2006) A246
8. Berendse H.W., and Groenewegen H.J. Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat. Neuroscience 42 (1991) 73-102
9. Bleakman D., Ballyk B.A., Schoepp D.D., Palmer A.J., Bath C.P., Sharpe E.F., et al. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology 35 (1996) 1689-1702
10. Bleakman D., Ogden A.-M., Ornstein P.L., and Hoo K. Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons. Eur J Pharmacol 378 (1999) 331-337
11. Carli M., and Samanin R. Serotonin2 receptor agonists and serotonergic anorectic drugs affect rats' performance differently in a five-choice serial reaction time task. Psychopharmacology 106 (1992) 228-234
12. Carli M., Baviera M., Invernizzi R.W., and Balducci C. The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 29 (2004) 1637-1647
13. Cartmell J., Monn J.A., and Schoepp D.D. The mGlu2/3 receptor agonists, LY354740 and LY379268, selectively attenuate phencyclidine versus d-amphetamine motor behavior in rats. J Pharmacol Exp Ther 291 (1999) 161-170
14. Cartmell J., Monn J.A., and Schoepp D.D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 148 (2000) 423-429
15. Ceglia I., Carli M., Baviera M., Renoldi G., Calcagno E., and Invernizzi R.W. The 5-HT2A receptor antagonist M100,907 prevents extracellular glutamate rising in response to NMDA receptor blockade in the mPFC. J Neurochem 91 (2004) 189-199
16. Connors B.W., and Gutnick M.J. Intrinsic firing patterns of diverse neocortical neurons. Trends Neurosci 13 (1990) 99-104
17. Corbett R., Zhou L., Sorenson S.M., and Mondadori C. Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology 21 (1999) S211-S218
18. Cornea-Hebert V., Riad M., Wu C., Singh S.K., and Descarries L. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of the rat. J Comp Neurol 409 (1999) 187-209
19. Cotton J.L., and Partin K.M. The contributions of GluR2 to allosteric modulation of AMPA receptors. Neuropharmacology 39 (2000) 21-31
20. Dall'Olio R., Gaggi R., Bonfante V., and Gandolfi O. The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol 10 (1999) 63-71
21. Galici R., Echemendia N.G., Rodriquez A.L., and Conn P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315 (2005) 1181-1187
22. Gewirtz J.C., and Marek G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23 (2000) 569-576
23. Gingrich J.A., Zhou M., Sealfon S., and Hen R. Mice lacking the 5-HT2A receptor are insensitive to many of the behavioral and physiological effects of hallucinogens. Soc Neurosci Abstr 25 (1999) 799
24. Gleason S.D., and Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzepine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129 (1997) 79-84
25. Gonzalez-Maeso J., Weisstaub N.V., Zhou M., Chan P., Ivic L., Ang R., et al. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signalling pathways to affect behavior. Neuron 53 (2007) 439-452
26. Gouzoulis-Mayfrank E., Heekeren K., Neukirch A., Stoll M., Stock C., Obradovic M., et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine: a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38 (2005) 301-311
27. Granhoff M.I., Lee L., Jackson A., Patel K., Martinez Y., Ashby C.R., et al. The interaction of 5-HT1A and 5-HT2 receptors in the medial prefrontal cortex: behavioral studies. Soc Neurosci Abstr 18 (1992) 1380
28. Habara T., Hamamura T., Miki M.J., Ohashi K., and Kuroda S. M100907, a selective 5-HT (2A) receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain. Eur J Pharmacol 417 (2001) 189-194
29. Hauber W., and Andersen R. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA receptor antagonist dizocilpine. Naunyn Schmiedebergs Arch Pharmacol 348 (1993) 486-490
30. Higgins G.A., Enderlin M., Haman M., and Fletcher P.J. The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviors produced by NMDA receptor antagonism. Psychopharmacology 170 (2003) 309-319
31. Jakab R.L., and Goldman-Rakic P.S. Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol 417 (2000) 337-348
32. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
33. Jodo E., Suzuki Y., Katayama T., Hoshino K.-Y., Takeuchi S., Niwa S.-I., et al. Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. Cereb Cortex 15 (2004) 663-669
34. Johnson M.P., Barda D., Britton T.C., Emkey R., Hornback W.J., Jagdmann G.E., et al. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179 (2005) 271-283
35. Kim H.-S., Park I.-S., and Park W.-K. NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice. Life Sci 63 (1998) 2305-2311
36. Kim H.-S., Son Y.-R., and Kim S.-H. Nitric oxide synthase inhibitors enhance 5-HT2 receptor-mediated behavior, the head-twitch response in mice. Life Sci 64 (1999) 2463-2470
37. Klodzinska A., Bijak M., Tokarski K., and Pilc A. Group II mGlu receptor agonists inhibit behavioral and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav 73 (2002) 327-332
38. Koskinen T., Ruotsalainen S., Puumala T., Lappalainen R., Koivisto E., Mannisto P.T., et al. Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task. Neuropharmacology 39 (2000) 471-481
39. Lambe E.K., and Aghajanian G.K. The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex. J Neurosci 21 (2001) 9955-9963
40. Lopez-Gil, X. Babot, Z. Amargos-Bosch, M. Sunol, C. Artigas, F. Adell, A. in press. Clozapine and haloperidol differentially suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology.; in press.
41. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., and Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neurosci 117 (2003) 697-706
42. Marek G.J., and Aghajanian G.K. 5-HT2A or a1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367 (1999) 197-206
43. Marek G.J., Wright R.A., Schoepp D.D., Monn J.A., and Aghajanian G.K. Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292 (2000) 76-87
44. Marek G.J., Wright R.A., Gewirtz J.C., and Schoepp D.D. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neurosci 105 (2001) 379-392
45. Marek G.J., Wright R.A., and Schoepp D.D. 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: Interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neurosci Lett 403 (2006) 256-260
46. Martin P., Waters N., Carlsson A., and Carlsson M.L. The apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural Transm 104 (1997) 561-564
47. Maurel-Remy S., Bervoets K., and Millan M.J. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280 (1995) R9-R11
48. McCormick D.A., Connors B.W., Lighthall J.W., and Prince D.A. Comparative electrophysiology of pyramidal and sparsely spiny neurons of the neocortex. J Neurophysiol 54 (1985) 782-806
49. Miner L.A.H., Backstrom J.R., Sanders-Bush E., and Sesack S.R. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neurosci 116 (2003) 107-117
50. Moghaddam B., and Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonists in rats. Science 281 (1998) 1349-1352
51. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from the NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17 (1997) 2921-2927
52. Murphy E.R., Dalley J.W., and Robbins T.W. Local glutamate receptor activation antagonism in the rat prefrontal cortex disrupts response inhibition in a visualspatial attentional task. Psychopharmacology 179 (2005) 99-107
53. Muschamp J.W., Regina M.J., Hull E.M., Winter J.C., and Rabin R.A. Lysergic acid diethylamide and (-)-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex. Brain Res 1023 (2004) 134-140
54. Patil ST, Zhang LX, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Nezanov N, Reznik AM, Smulevich AB, Tochilov VA, Monn JA, Johnson BG, Schoepp DD in press. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: results from a randomized Phase 2 clinical trial. Nature Medicine.
55. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1997), Academic Press Inc, San Diego
56. Pei Q., Tordera R., Sprakes M., and Sharp T. Glutamate receptor activation is involved in 5-HT2 agonist-induced Arc gene expression in the rat cortex. Neuropharmacology 46 (2004) 331-339
57. Puig M.V., Celada P., Diaz-Mataix L., and Artigas F. In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors. Relationship to thalamocortical afferents. Cereb Cortex 13 (2003) 870-882
58. Schoepp D.D. New directions in the treatment of schizophrenia: modulators of mGlu2 and/or mGlu3 receptors. Neuropsychopharmacology 31 (2006) S25
59. Schoepp D.D., Lodge D., Bleakman D., Leander J.D., Tizzano J.P., Wright R.A., et al. In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3 carboxylic acid. Neuropharmacology 34 (1995) 1159-1168
60. Schreiber R., Brocco M., Audinot V., Gobert A., Veiga S., and Millan M.J. (1-(2,5-Dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine(5-HT)2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273 (1995) 101-112
61. Scruggs J.L., Patel S., Bubser M., and Deutch A.Y. DOI-induced activation of the cortex: dependence upon 5-HT2A heteroceptors on thalamocortical glutamatergic neurons. J Neurosci 20 (2000) 8846-8852
62. Simmons R.M.A., Li D.L., Hoo K.H., Deverill M., Ornstein P.L., and Iyengar S. Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 37 (1998) 25-36
63. Vollenweider F.X., Leenders K.L., Scharfetter C., Antonini A., Maguire P., Missimer J., et al. Metabolic hyerfrontality and psychopathology in the ketamine model of psychosis using emission tomography (PET) and [18F] fluorodeoxyglucose (FDG). Eur Neuropsychopharm 7 (1997) 9-24
64. Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., and Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyerfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16 (1997) 357-372
65. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F.I., Babler A., Vogel H., and Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9 (1998) 3897-3902
66. Weisstaub N.V., Zhou M., Lira A., Lambe E.K., Gonzalez-Maeso J., Hornung J.-P., et al. Cortical 5-HT2A receptor signalling modulates anxiety-like behaviors in mice. Science 313 (2006) 536-540
67. Willins D.L., Deutch A.Y., and Roth B.L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27 (1997) 79-82
68. Willins D.L., and Meltzer H.Y. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282 (1997) 699-706
69. Woolley D.W., and Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci U S A 40 (1954) 228-231
70. Xu T., and Pandey S.C. Cellular localization of serotonin2A (5-HT2A) receptors in rat brain. Brain Res Bull 51 (2000) 499-505
71. Zhai Y., George C.A., Zhai J., Nisenbaum E.S., Johnson M.P., and Nisenbaum L.K. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28 (2003) 45-52
72. Zhang C., and Marek G.J. Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor stimulation. J Pharmacol Exp Ther 320 (2007) 437-447